Split History
ETFs Holding CALA »    CALA Historical Stock Prices »
Video: What is a Stock Split?


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Calithera Biosciences is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule oncology drugs directed against tumor and immune cell targets for tumor microenvironment. Co.'s product candidates: CB-839, which is an internally discovered, oral inhibitor of glutaminase, a critical enzyme in tumor cells; and CB-1158, which is an oral inhibitor of arginase, an enzyme that depletes the amino acid arginine, a key metabolic nutrient for T-cells. Co.'s program in tumor metabolism is focused on the hexokinase II enzyme. Co.'s preclinical program in tumor immunology is focused on developing selective inhibitors of the enzyme arginase. According to our CALA split history records, Calithera Biosciences has had 1 split.
CALA split history picture
Calithera Biosciences (CALA) has 1 split in our CALA split history database. The split for CALA took place on July 17, 1996. This was a 2 for 1 split, meaning for each share of CALA owned pre-split, the shareholder now owned 2 shares. For example, a 1000 share position pre-split, became a 2000 share position following the split.

When a company such as Calithera Biosciences splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business. Looking at the CALA split history from start to finish, an original position size of 1000 shares would have turned into 2000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Calithera Biosciences shares, starting with a $10,000 purchase of CALA, presented on a split-history-adjusted basis factoring in the complete CALA split history. CALA split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 04/24/2007
End date: 04/21/2017
Start price/share: $7.00
End price/share: $11.25
Dividends collected/share: $0.00
Total return: 60.71%
Average Annual Total Return: 4.86%
Starting investment: $10,000.00
Ending investment: $16,073.06
Years: 10.00
Date Ratio
07/17/19962 for 1
CALA is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

CAPR Split History
CASC Split History
CBIO Split History
CBLI Split History
CBM Split History
CBMX Split History
CBRX Split History
CCM Split History
CDXC Split History
CELG Split History

Rexahn Pharmaceuticals, Inc. (RNN)
Immune Pharmaceuticals Inc. (INMP)
DryShips Inc. (DRYS)
STRATA Skin Sciences, Inc. (SSKN)
Quantum Corp. (QTM)
German American Bancorp, Inc. (GABC)
Pacific Energy Development (PED)
The GEO Group, Inc. (GEO)
Copart, Inc. (CPRT)
HEICO Corporation (HEI)
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

CALA Insider Buying

CALA Split History | www.SplitHistory.com | Copyright © 2013 - 2017, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.